Anisodine

Abstract

Anisodine was separated from the herbal medicine Anisodus tanguticus from Qinghai province, and its hydrobromide form was an originally created new drug in China. It competes with acetylcholine in the M cholinergic receptor to prevent acetylcholine from binding M cholinergic receptor, thus blocking the nerve impulse transmission and interfering with the physiological function based on the cholinergic neurotransmission. Anisodine has weaker intensity of action than atropine, as well as toxicity. Oral anisodine is absorbed rapidly and completely. At first, anisodine was mainly used in the treatment of various diseases of the central nervous system. The efficacy of anisodine for the treatment of cerebrovascular disease was validated from 1970 to 1975. Recently, compound anisodine injection based on a combination of procaine and anisodine hydrobromide showed a good effect for a variety of ischemic eye diseases induced by a variety of causes and other related eye diseases, especially superior to traditional therapies for ischemic lesions of the optic nerve, retina, and choroid. This drug has been widely used in China to promote the treatment for various eye diseases which achieved exciting results.